๎
๎ผ
๎
ATAI Life Sciences NV
ATAI4.070USD
-0.120-2.86%
์ข
๊ฐย 12/26, 16:00๏ผET๏ผ์์ธ๋ 15๋ถ ์ง์ฐ๋ฉ๋๋ค
978.58M์๊ฐ์ด์ก
์์คP/E TTM
๎
์์ธํ ๋ด์ฉ์ ATAI Life Sciences NV ํ์ฌ
Atai Beckley NV, formerly ATAI Life Sciences NV, is a clinical-stage biopharmaceutical company. The Company focused on developing treatments for mental health disorders. The Company's pipeline includes psychedelic and non-psychedelic compounds targeting depression, anxiety, and other unmet needs in psychiatry.
ATAI Life Sciences NV ์ ๋ณด
๎์ข
๋ชฉ ์ฝ๋ ATAI
ํ์ฌ ์ด๋ฆAtai Beckley NV
์์ฅ์ผJun 18, 2021
CEORao (Srinivas G)
์ง์ ์54
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃJun 18
์ฃผ์Prof. J.H.Bavincklaan 7
๋์AMSTELVEEN
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐNetherlands
์ฐํธ ๋ฒํธ1183 AT
์ ํ31207932536
์น์ฌ์ดํธhttps://www.atai.com/
์ข
๋ชฉ ์ฝ๋ ATAI
์์ฅ์ผJun 18, 2021
CEORao (Srinivas G)
ATAI Life Sciences NV์ ํ์ฌ ์์์ง
๎์ด๋ฆ
์ด๋ฆ/์ง์
์ง์
์ฃผ์ ๋ณด์
๋ณ๋
Dr. Glenn Frank Short, Ph.D.
Dr. Glenn Frank Short, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
42.33K
+84.10%
Ms. Andrea Heslin Smiley
Ms. Andrea Heslin Smiley
Independent Supervisory Director
Independent Supervisory Director
4.67K
--
Dr. Amir Kalali
Dr. Amir Kalali
Independent Supervisory Director
Independent Supervisory Director
--
--
Dr. Kevin James Craig, M.D.
Dr. Kevin James Craig, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Anne Johnson
Ms. Anne Johnson
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Gerd G. Kochendoerfer
Dr. Gerd G. Kochendoerfer
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Christian Angermayer
Mr. Christian Angermayer
Chairman of the Supervisory Board
Chairman of the Supervisory Board
--
--
Ms. Sabrina Martucci Johnson
Ms. Sabrina Martucci Johnson
Independent Supervisory Director
Independent Supervisory Director
--
--
Dr. Srinivas Rao, M.D., Ph.D.
Dr. Srinivas Rao, M.D., Ph.D.
Chief Executive Officer, Co-Founder, Interim Managing Director
Chief Executive Officer, Co-Founder, Interim Managing Director
--
--
Dr. Laurent Fischer, M.D.
Dr. Laurent Fischer, M.D.
Independent Supervisory Director
Independent Supervisory Director
--
--
๋ ๋ณด๊ธฐ
์ด๋ฆ
์ด๋ฆ/์ง์
์ง์
์ฃผ์ ๋ณด์
๋ณ๋
Dr. Glenn Frank Short, Ph.D.
Dr. Glenn Frank Short, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
42.33K
+84.10%
Ms. Andrea Heslin Smiley
Ms. Andrea Heslin Smiley
Independent Supervisory Director
Independent Supervisory Director
4.67K
--
Dr. Amir Kalali
Dr. Amir Kalali
Independent Supervisory Director
Independent Supervisory Director
--
--
Dr. Kevin James Craig, M.D.
Dr. Kevin James Craig, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Anne Johnson
Ms. Anne Johnson
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Gerd G. Kochendoerfer
Dr. Gerd G. Kochendoerfer
Chief Operating Officer
Chief Operating Officer
--
--
์์ต ๋ถ์
๊ธฐ์
์ด ์์ง ๊ด๋ จ ๋ฐ์ดํฐ๋ฅผ ๊ณต๊ฐํ์ง ์์์ต๋๋ค.
๊ธฐ์
์ด ์์ง ๊ด๋ จ ๋ฐ์ดํฐ๋ฅผ ๊ณต๊ฐํ์ง ์์์ต๋๋ค.
์ฌ์
๋ณ
์ง์ญ๋ณ
๊ธฐ์
์ด ์์ง ๊ด๋ จ ๋ฐ์ดํฐ๋ฅผ ๊ณต๊ฐํ์ง ์์์ต๋๋ค.
์ฃผ์ ๋ณด์ ํต๊ณ
๋ง์ง๋ง ์
๋ฐ์ดํธ: Fri, Dec 12
๋ง์ง๋ง ์
๋ฐ์ดํธ: Fri, Dec 12
์ฃผ์ฃผ
์ฃผ์ฃผ ์ ํ
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น์จ
Apeiron Investment Group Ltd
15.20%
Feilding-Mellen (Cosmo)
2.12%
UBS Financial Services, Inc.
1.72%
Adage Capital Management, L.P.
1.50%
Brand (Florian Olaf)
1.39%
๊ธฐํ
78.08%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น์จ
Apeiron Investment Group Ltd
15.20%
Feilding-Mellen (Cosmo)
2.12%
UBS Financial Services, Inc.
1.72%
Adage Capital Management, L.P.
1.50%
Brand (Florian Olaf)
1.39%
๊ธฐํ
78.08%
์ฃผ์ฃผ ์ ํ
์ฃผ์ฃผ
๋น์จ
Family Office
15.21%
Investment Advisor
4.61%
Hedge Fund
4.11%
Individual Investor
3.70%
Investment Advisor/Hedge Fund
1.83%
Research Firm
1.23%
Bank and Trust
0.40%
Private Equity
0.39%
Endowment Fund
0.20%
๊ธฐํ
68.33%
๊ธฐ๊ด ์ฃผ์ ๋ณด์
๎๋ง์ง๋ง ์
๋ฐ์ดํธ: Mon, Dec 8
๋ง์ง๋ง ์
๋ฐ์ดํธ: Mon, Dec 8
๋ณด๊ณ ๊ธฐ๊ฐ
๊ธฐ๊ด ์
๋ณด์ ์ฃผ์
๋น์จ
๋ณ๋
2025Q4
218
45.07M
10.88%
+16.45K
2025Q3
249
45.57M
19.55%
+12.66M
2025Q2
225
29.96M
14.58%
+6.94M
2025Q1
223
23.03M
12.83%
-2.41M
2024Q4
236
15.60M
13.86%
+2.09M
2024Q3
236
13.53M
16.71%
-545.79K
2024Q2
246
14.10M
16.43%
-259.20K
2024Q1
244
14.41M
17.26%
-14.24M
2023Q4
251
15.93M
17.75%
-1.57M
2023Q3
259
17.69M
19.30%
-562.50K
๋ ๋ณด๊ธฐ
์ฃผ์ฃผ ํ๋
๎์ด๋ฆ
๋ณด์ ์ฃผ์
๋น์จ
๋ณ๋
Chg %
๋ ์ง
Apeiron Investment Group Ltd
55.20M
25.75%
+2.37M
+4.48%
Sep 30, 2025
UBS Financial Services, Inc.
7.08M
3.3%
+3.21M
+83.06%
Jun 30, 2025
Adage Capital Management, L.P.
5.43M
2.54%
+5.43M
--
Jun 30, 2025
Brand (Florian Olaf)
5.04M
2.35%
-250.00K
-4.73%
Sep 15, 2025
Morgan Stanley Investment Management Inc. (US)
1.85M
0.86%
+4.04K
+0.22%
Jun 30, 2025
Citadel Advisors LLC
1.18M
0.55%
+1.15M
+4612.14%
Jun 30, 2025
ARK Investment Management LLC
1.55M
0.72%
-59.62K
-3.71%
Aug 31, 2025
๋ ๋ณด๊ธฐ
๊ด๋ จ ETF
๎๋ง์ง๋ง ์
๋ฐ์ดํธ: Sat, Dec 6
๋ง์ง๋ง ์
๋ฐ์ดํธ: Sat, Dec 6
์ด๋ฆ
๋น์จ
AdvisorShares Psychedelics ETF
17.55%
ARK Genomic Revolution ETF
1.6%
Invesco NASDAQ Future Gen 200 ETF
0.69%
Even Herd Long Short ETF
0.14%
Avantis US Small Cap Equity ETF
0.08%
First Trust IPOX Europe Equity Opportunities ETF
0.06%
SPDR S&P International Small Cap ETF
0.05%
Fidelity Nasdaq Composite Index ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
Avantis US Equity ETF
0%
๋ ๋ณด๊ธฐ
AdvisorShares Psychedelics ETF
๋น์จ17.55%
ARK Genomic Revolution ETF
๋น์จ1.6%
Invesco NASDAQ Future Gen 200 ETF
๋น์จ0.69%
Even Herd Long Short ETF
๋น์จ0.14%
Avantis US Small Cap Equity ETF
๋น์จ0.08%
First Trust IPOX Europe Equity Opportunities ETF
๋น์จ0.06%
SPDR S&P International Small Cap ETF
๋น์จ0.05%
Fidelity Nasdaq Composite Index ETF
๋น์จ0%
ProShares Ultra Nasdaq Biotechnology
๋น์จ0%
Avantis US Equity ETF
๋น์จ0%
์ฃผ์ ๋ฐฐ๋น๊ธ
๎์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.
๋ ์ง
๋ฐฐ๋น๊ธ
๊ธฐ์ค์ผ
์ง๊ธ์ผ
๋ฐฐ๋น๋ฝ์ผ
๋ฐ์ดํฐ ์์
์ฃผ์ ๋ถํ
๎๋ ์ง
์ ํ
๋น์จ
๋ฐ์ดํฐ ์์
๋ ์ง
์ ํ
๋น์จ
๋ฐ์ดํฐ ์์
์์ฃผ ๋ฌป๋ ์ง๋ฌธ
ATAI Life Sciences NV์ ์์ 5๋ ์ฃผ์ฃผ๋ ๋๊ตฌ์ธ๊ฐ์?
๎ATAI Life Sciences NV์ ์์ 5๋ ์ฃผ์ฃผ๋ ๋ค์๊ณผ ๊ฐ์ต๋๋ค:
Apeiron Investment Group Ltd๋ 55.20M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 25.75%๋ฅผ ์ฐจ์งํฉ๋๋ค.
UBS Financial Services, Inc.๋ 7.08M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 3.30%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Adage Capital Management, L.P.๋ 5.43M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 2.54%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Brand (Florian Olaf)๋ 5.04M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 2.35%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Morgan Stanley Investment Management Inc. (US)๋ 1.85M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 0.86%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Apeiron Investment Group Ltd๋ 55.20M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 25.75%๋ฅผ ์ฐจ์งํฉ๋๋ค.
UBS Financial Services, Inc.๋ 7.08M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 3.30%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Adage Capital Management, L.P.๋ 5.43M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 2.54%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Brand (Florian Olaf)๋ 5.04M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 2.35%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Morgan Stanley Investment Management Inc. (US)๋ 1.85M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 0.86%๋ฅผ ์ฐจ์งํฉ๋๋ค.
ATAI Life Sciences NV์ ์์ 3๋ ์ฃผ์ฃผ ์ ํ์ ๋ฌด์์ธ๊ฐ์?
๎ATAI Life Sciences NV์ ์ฃผ์ ์ฃผ์ฃผ ์ ํ ์์ 3๊ฐ์ง๋
Apeiron Investment Group Ltd
Feilding-Mellen (Cosmo)
UBS Financial Services, Inc.์ ๋๋ค.
Apeiron Investment Group Ltd
Feilding-Mellen (Cosmo)
UBS Financial Services, Inc.์ ๋๋ค.
ATAI Life Sciences NV(ATAI)์ ์ฃผ์์ ๋ณด์ ํ ๊ธฐ๊ด์ ๋ช ๊ฐ์ ๋๊น?
๎2025Q4 ๊ธฐ์ค์ผ๋ก, ATAI Life Sciences NV์ ์ฃผ์์ ๋ณด์ ํ ๊ธฐ๊ด์ ์ด 218๊ณณ์ด๋ฉฐ, ์ด๋ค์ด ๋ณด์ ํ ์ฃผ์์ ์ด ๊ฐ์น๋ ์ฝ 45.07M๋ก ์ ์ฒด ๋ฐํ ์ฃผ์์ 10.88%๋ฅผ ์ฐจ์งํฉ๋๋ค. ์ด๋ 2025Q3 ๋๋น -8.67% ์ฆ๊ฐํ ์์น์
๋๋ค.
ATAI Life Sciences NV์ ์ต๋ ์์ต์์ ๋ฌด์์ธ๊ฐ์?
๎-- ๊ธฐ์ค, ATAI Life Sciences NV์ -- ๋ถ๋ฌธ์ด ๊ฐ์ฅ ๋์ ๋งค์ถ์ ๊ธฐ๋กํ์ผ๋ฉฐ, ๊ธ์ก์ --๋ก ์ ์ฒด ๋งค์ถ์ --%๋ฅผ ์ฐจ์งํ์ต๋๋ค.
